Ravichandran Vishwa

Ravichandran Vishwa

Auto-generated profile, based on publicly available information

Ravichandran Vishwa

Cancer Biology Laboratory, Department of Biosciences and Bioengineering Indian Institute of Technology Guwahati (IITG) Guwahati India

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2023 in ACS Omega
Verified
Journal Article
Open access
MHMangala Hegde
Mangala Hegde
SGSosmitha Girisa
Sosmitha Girisa
BCBandari Bharathwaj Chetty
Bandari Bharathwaj Chetty
RVRavichandran Vishwa
Ravichandran Vishwa
AKAjaikumar B. Kunnumakkara
Ajaikumar B. Kunnumakkara
Curcumin has been credited with a wide spectrum of pharmacological properties for the prevention and treatment of several chronic diseases such as arthritis, autoimmune diseases, cancer, cardiovascular diseases, diabetes, hemoglobinopathies, hypertension, infectious diseases, inflammation, metabolic syndrome, neurological diseases, obesity, and skin diseases. However, due to its weak solubility and bioavailability, it has limited potential as an oral medication. Numerous factors including low water solubility, poor intestinal permeability, instability at alkaline pH, and fast metabolism contribute to curcumin's limited oral bioavailability. In order to improve its oral bioavailability, different formulation techniques such as coadministration with piperine, incorporation into micelles, micro/nanoemulsions, nanoparticles, liposomes, solid dispersions, spray drying, and noncovalent complex formation with galactomannosides have been investigated with in vitro cell culture models, in vivo animal models, and humans. In the current study, we extensively reviewed clinical trials on various generations of curcumin formulations and their safety and efficacy in the treatment of many diseases. We also summarized the dose, duration, and mechanism of action of these formulations. We have also critically reviewed the advantages and limitations of each of these formulations compared to various placebo and/or available standard care therapies for these ailments. The highlighted integrative concept embodied in the development of next-generation formulations helps to minimize bioavailability and safety issues with least or no adverse side effects and the provisional new dimensions presented in this direction may add value in the prevention and cure of complex chronic diseases.

22 March 2024 in Cancer and Metastasis Reviews
Verified
Journal Article
Closed access
PDF file
BCBandari Bharathwaj Chetty
Bandari Bharathwaj Chetty
ASAnjana Sajeev
Anjana Sajeev
RVRavichandran Vishwa
Ravichandran Vishwa
AAAswani Babu Santha Aswani
Aswani Babu Santha Aswani
MAMohammed Alqahtani
Mohammed Alqahtani
AKAjaikumar B. Kunnumakkara
Ajaikumar B. Kunnumakkara

17 October 2023 in Non-Coding RNA
Verified
Journal Article
Open access
PDF file
ASAnjana Sajeev
Anjana Sajeev
BCBandari Bharathwaj Chetty
Bandari Bharathwaj Chetty
RVRavichandran Vishwa
Ravichandran Vishwa
MAMohammed Alqahtani
Mohammed Alqahtani
MAMohamed Abbas
Mohamed Abbas
AKAjaikumar B. Kunnumakkara
Ajaikumar B. Kunnumakkara
Head and neck cancers (HNC) encompass a broad spectrum of neoplastic disorders characterized by significant morbidity and mortality. While contemporary therapeutic interventions offer promise, challenges persist due to tumor recurrence and metastasis. Central to HNC pathogenesis is the aberration in numerous signaling cascades. Prominently, the Wnt signaling pathway has been critically implicated in the etiology of HNC, as supported by a plethora of research. Equally important, variations in the expression of non-coding RNAs (ncRNAs) have been identified to modulate key cancer phenotypes such as cellular proliferation, epithelial-mesenchymal transition, metastatic potential, recurrence, and treatment resistance. This review aims to provide an exhaustive insight into the multifaceted influence of ncRNAs on HNC, with specific emphasis on their interactions with the Wnt/β-catenin (WBC) signaling axis. We further delineate the effect of ncRNAs in either exacerbating or attenuating HNC progression via interference with WBC signaling. An overview of the mechanisms underlying the interplay between ncRNAs and WBC signaling is also presented. In addition, we described the potential of various ncRNAs in enhancing the efficacy of chemotherapeutic and radiotherapeutic modalities. In summary, this assessment posits the potential of ncRNAs as therapeutic agents targeting the WBC signaling pathway in HNC management.

27 October 2025 in Journal of Biochemical and Molecular Toxicology
Verified
Journal Article
Closed access
RVRavichandran Vishwa
Ravichandran Vishwa
BSBethsebie Lalduhsaki Sailo
Bethsebie Lalduhsaki Sailo
BCBandari Bharathwaj Chetty
Bandari Bharathwaj Chetty
MHMangala Hegde
Mangala Hegde
MAMohammed Alqahtani
Mohammed Alqahtani
AKAjaikumar B. Kunnumakkara
Ajaikumar B. Kunnumakkara